Explore
Validate
Learn
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [0]
- Comments [0]
- Validations
- Western blot [1]
- ELISA [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- RA0267 - Provider product page
- Provider
- Oursmab
- Product name
- Naxitamab (Biosimilar Reference Antibody) (Ganglioside GD2)
- Antibody type
- Monoclonal
- Description
- Naxitamab (brand name Danyelza?) is a humanized monoclonal antibody that targets GD2 (disialoganglioside GD2), a glycolipid antigen highly expressed on neuroblastoma cells and some other solid tumors (e.g., osteosarcoma, melanoma). It is an IgG1 isotype engineered to enhance antibody-dependent cellular cytotoxicity (ADCC). By binding to GD2, naxitamab directs immune cells (primarily natural killer cells and macrophages) to attack GD2-positive tumor cells. It is approved in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy.
- Reactivity
- Human
- Isotype
- IgG
- Vial size
- 100 ¦Ìg,1 mg,5 mg-500,10 mg,25 mg,50 mg,177 mg
- Concentration
- Bottled at the concentration indicated on the vial.
- Storage
- Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.
No comments: Submit comment
Supportive validation
- Submitted by
- Oursmab (provider)
- Main image
- Experimental details
- Naxitamab (Biosimilar Reference Antibody) (Ganglioside GD2)-RA0267-Oursmab determined by SDS-PAGE. The purity of the protein is greater than 98%.
Supportive validation
- Submitted by
- Oursmab (provider)
- Main image
- Experimental details
- ELISA plate pre-coated Antigen protein, can bind Naxitamab (Biosimilar Reference Antibody) (Ganglioside GD2)-RA0267 in a linear range of 3.91¨C31 ng/mL.
